Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CDK4/6 Inhibitor”

233 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 233 results

Early research (Phase 1)Study completedNCT02370706
What this trial is testing

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Who this might be right for
Myelofibrosis
Novartis Pharmaceuticals 15
Testing effectiveness (Phase 2)Looking for participantsNCT05933395
What this trial is testing

Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor

Who this might be right for
Advanced Breast Cancer
Dartmouth-Hitchcock Medical Center 135
Testing effectiveness (Phase 2)Active Not RecruitingNCT03090165
What this trial is testing

Ribociclib and Bicalutamide in AR+ TNBC

Who this might be right for
Triple Negative Breast Cancer
Kari Wisinski 37
Early research (Phase 1)Looking for participantsNCT05372640
What this trial is testing

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma+5 more
National Cancer Institute (NCI) 45
Not applicableNot Yet RecruitingNCT07190651
What this trial is testing

Development of a New Remote Monitoring Model for Patients With HR+HER2- Breast Cancer in Treatment With CDK4/6 Inhibitors and Hormone Therapy

Who this might be right for
Breast CancerCDK4/6 Inhibitor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 50
Not applicableLooking for participantsNCT07180056
What this trial is testing

Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
Wenjin Yin 229
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05986071
What this trial is testing

I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers

Who this might be right for
Breast Cancer
Institut Paoli-Calmettes 57
Early research (Phase 1)Looking for participantsNCT06586957
What this trial is testing

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Who this might be right for
Solid TumorAdvanced Solid TumorSolid Tumor, Adult+25 more
NiKang Therapeutics, Inc. 150
Post-approval studies (Phase 4)Ended earlyNCT04031885
What this trial is testing

Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 4
Early research (Phase 1)Ended earlyNCT04162301
What this trial is testing

CS3002 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
CStone Pharmaceuticals 10
Large-scale testing (Phase 3)Active Not RecruitingNCT04964934
What this trial is testing

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

Who this might be right for
ER-Positive HER2-Negative Breast Cancer
AstraZeneca 315
Testing effectiveness (Phase 2)UnknownNCT03601598
What this trial is testing

A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC

Who this might be right for
CRCHCCNSCLC
Harbin Medical University 41
Testing effectiveness (Phase 2)Study completedNCT02514447
What this trial is testing

Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy

Who this might be right for
Small Cell Lung Cancer
G1 Therapeutics, Inc. 123
Testing effectiveness (Phase 2)UnknownNCT05512416
What this trial is testing

Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer

Who this might be right for
Breast Cancer
The Affiliated Hospital of Qingdao University 35
Large-scale testing (Phase 3)Not Yet RecruitingNCT06996093
What this trial is testing

Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor

Who this might be right for
Breast Cancer
Fudan University 2,508
Large-scale testing (Phase 3)Active Not RecruitingNCT06612814
What this trial is testing

PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

Who this might be right for
Breast Cancer Metastatic
Zhimin Shao 307
Testing effectiveness (Phase 2)UnknownNCT04733417
What this trial is testing

SHR6390 Combined With Famitinib in the Treatment of HR + / HER2- Advanced Breast Cancer.

Who this might be right for
Advanced Breast CancerMetastatic Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 35
Testing effectiveness (Phase 2)Ended earlyNCT03584009
What this trial is testing

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

Who this might be right for
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Hoffmann-La Roche 103
Testing effectiveness (Phase 2)Active Not RecruitingNCT01723774
What this trial is testing

PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Who this might be right for
Breast Neoplasms
Washington University School of Medicine 84
Early research (Phase 1)Study completedNCT02499146
What this trial is testing

Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 26
Load More Results